Over the past three months, six analysts have evaluated Zymeworks (NASDAQ:ZYME), showing a range of opinions from bullish to bearish. The average 12-month price target is $12.0, with a high of $16.00 and a low of $10.00. Recent analyst actions include maintaining, raising, and lowering ratings and price targets.